Organization Profile

You just read:

Health Canada's approval of Taltz™ (ixekizumab) Brings Targeted Therapy to Canadians Living with Moderate-to-Severe Plaque Psoriasis

News provided by

Eli Lilly Canada Inc.

Jun 21, 2016, 12:42 ET